Breo Ellipta is owned by Glaxo Grp Ltd.
Breo Ellipta contains Fluticasone Furoate; Vilanterol Trifenatate.
Breo Ellipta has a total of 10 drug patents out of which 1 drug patent has expired.
Expired drug patents of Breo Ellipta are:
Breo Ellipta was authorised for market use on 10 May, 2013.
Breo Ellipta is available in powder;inhalation dosage forms.
Breo Ellipta can be used as indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations, indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations, indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older, indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; indicated for the once-daily treatment of asthma in patients 18 years and older; indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations.
The generics of Breo Ellipta are possible to be released after 11 October, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(2 days from now) | |
US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7776895 | GLAXO GRP LTD | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(6 months ago) | |
US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(4 years from now) | |
US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(4 years from now) | |
US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(4 years from now) | |
US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(5 years from now) | |
US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(6 years from now) | |
US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(7 years from now) |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; For the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; Indicated for the once-daily treatment of asthma in patients 18 years and older
Dosage: POWDER;INHALATION
27
United States
24
European Union
17
United Kingdom
13
Japan
11
Spain
10
Brazil
10
China
10
Australia
10
Denmark
9
Portugal
9
Poland
8
South Africa
8
Canada
8
Cyprus
7
Mexico
7
Korea, Republic of
7
Hong Kong
6
Norway
6
Hungary
5
New Zealand
5
Israel
3
Argentina
3
Slovenia
2
Germany
2
Singapore
2
Malaysia
2
Russia
2
Colombia
2
Austria
2
Taiwan, Province of China
1
Croatia
1
Belgium
1
Lithuania
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic